 |
Pramiracetam Sulfate |
|---|---|
| Trade Name | |
| Orphan Indication | For the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy |
| USA Market Approval | USA |
| USA Designation Date | 1991-11-04 00:00:00 |
| Sponsor | Cambridge Neuroscience, Inc.;1 Kendall Square, Bldg. 700;Cambridge, Massachusetts, 02139 |
